Updated Jul 16, 2026
Brainard Diana is a corporate insider tracked by InsiderAlpha. No SEC Form 4 filings recorded in the last 90 days. Lifetime open-market sales: $23K.
Diana Brainard is the Chief Executive Officer of Nektar Therapeutics, a biopharmaceutical company specializing in immunotherapy. She has held various roles in the pharmaceutical industry, contributing to drug discovery and development.
| Role | Insider |
|---|---|
| Notability | 50/100 |
| Date | Ticker | Company | Code | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2024-11-20 | KLRS | Kalaris Therapeutics, Inc. | S — Open-market sale | 8.7K | $0.55 | $5K |
| 2024-11-06 | KLRS | Kalaris Therapeutics, Inc. | S — Open-market sale | 10.6K | $0.86 | $9K |
| 2024-10-23 | KLRS | Kalaris Therapeutics, Inc. | S — Open-market sale | 9.8K | $0.78 | $8K |
| 2024-10-04 | KLRS | Kalaris Therapeutics, Inc. | S — Open-market sale | 1.5K | $0.81 | $1K |
Diana Brainard is the Chief Executive Officer of Nektar Therapeutics, a biopharmaceutical company specializing in immunotherapy. She has held various roles in the pharmaceutical industry, contributing to drug discovery and development.…
Recorded transactions: 0 open-market purchases () and 4 open-market sales ($23K) across all tracked filings.
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Open the live Brainard Diana profile on InsiderAlpha for real-time alerts, AI-scored trade ideas, and full transaction history.